SFG
AKTX

Skyview Financial Group’s Akari Therapeutics AKTX Stock Holding History

Skyview Financial Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.95K Buy
+514
New +$11.9K 0.01% 57

Other funds holding AKTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Skyview Financial Group's AKTX Position: Q4 2025 in Review

Skyview Financial Group opened a new position in Akari Therapeutics (AKTX) in Q4 2025: 514 shares worth $5.95K. The stake represents 0.01% of the portfolio and ranks #57 among its holdings.

19 funds tracked by Wall St. Rank hold AKTX as of Q4 2025.

  • Skyview Financial Group held 514 shares of Akari Therapeutics worth $5.95K as of Q4 2025.
  • Akari Therapeutics was a new Skyview Financial Group position in Q4 2025.
  • Akari Therapeutics made up 0.01% of Skyview Financial Group's portfolio in Q4 2025, its #57 holding.
  • 19 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2025.

Based on Skyview Financial Group's 13F filing for Q4 2025, filed 18 Feb 2026.